01 /

Cascade, founded in December 2017, is a Sino-foreign joint venture biomedical enterprise, focusing on innovative drugs targeting nuclear receptors and G protein coupled receptors (GPCRs). The core R&D team is jointly led by internationally renowned structural biologists and top nuclear receptor scientists. The team has accumulated more than 20 years of innovative drug research and development in the fields of metabolic diseases, tumor and inflammation targeting nuclear receptors, leading the way in structure based drug design. Cascade, concentrating on independent research and development, has established a rich and risk-balanced Class 1 new drug pipeline. Currently, there are a dozen of drug candidates, of which the core product of a non-cholic acid drug molecule CS0159 targeting FXR has completed US clinical Phase 1, and Phase 2 will be initiated immediately.The orphan drug designation (ODD) for primary sclerosing cholangitis (PSC) has been granted in September of 2021.

Cascade, founded in December 2017, is a Sino-foreign joint venture biomedical enterprise, focusing on innovative drugs targeting nuclear receptors and G protein coupled receptors (GPCRs). The core R&D team is jointly led by internationally renowned structural biologists and top nuclear receptor scientists. The team has accumulated more than 20 years of innovative drug research and development in the fields of metabolic diseases, tumor and inflammation targeting nuclear receptors, leading the way in structure based drug design. Cascade, concentrating on independent research and development, has established a rich and risk-balanced Class 1 new drug pipeline. Currently, there are a dozen of drug candidates, of which the core product of a non-cholic acid drug molecule CS0159 targeting FXR has completed US clinical Phase 1, and Phase 2 will be initiated immediately.The orphan drug designation (ODD) for primary sclerosing cholangitis (PSC) has been granted in September of 2021.

Research and development

Research & Development

  • Pipeline

    The core team has experience in the full life cycle of pharmaceutical research and development. The core pipeline is in the leading position among its peers, and other pipelines have unlimited potential. CS0159 targeting FXR has completed US clinical Phase 1, and Phase 2 will be initiated immediately; The orphan drug designation (ODD) for primary sclerosing cholangitis (PSC) has been granted in September of 2021. CS060304 has entered IND enabling in December of 2022. Multiple lead compounds have shown great efficacy in animal models and preclinical candidate compounds (PCCs) will soon to be determined in the near future.

    Learn More
  • Technology Platform

    At present, the company basically has perfect and full cycle preclinical R&D capabilities of new drugs, mainly including drug molecular design and synthesis platform, molecular cell analysis platform for in vitro efficacy and target verification, in vivo small animal efficacy evaluation platform, in vitro and in vivo drug metabolism analysis platform and general in vivo toxicology evaluation platform.

    Learn More
Learn MoreRecruitment
© 2020 凯思凯迪(上海)医药科技有限公司 All Rights Reserved.